ARDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ardelyx Inc (ARDX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The company's strong analyst ratings, upward price target revisions, positive news catalysts, and growth potential in its IBS-C market make it an attractive opportunity. Despite some technical neutrality and hedge fund selling, the long-term growth outlook and insider confidence outweigh short-term concerns.
The MACD is below 0 but negatively contracting, suggesting potential stabilization. RSI is neutral at 50.466, indicating no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key support is at 5.791, and resistance is at 7.151, with the stock closing at 6.6, near the pivot point.
Analysts have consistently raised price targets, with the highest at $19, citing strong growth potential and underpenetrated markets.
Insider buying by Chairman David Mott, who increased his stake by 11%, signals confidence.
A new patent extending IP to 2042 and a partnership with the LPGA to promote awareness of IBS-C.
Strong Q4 2025 revenue growth of 7.82% YoY and gross margin improvement to 91.34%.
Hedge funds have significantly increased selling activity by 129.11% over the last quarter.
Net income dropped significantly (-108.76% YoY), and EPS fell to 0, reflecting profitability challenges.
Broader market sentiment is bearish due to global tariff increases announced by President Trump.
In Q4 2025, revenue increased by 7.82% YoY to $125.2 million, and gross margin improved to 91.34%. However, net income dropped significantly to -$407,000 (-108.76% YoY), and EPS fell to 0 (-100% YoY). Despite these challenges, the company has a strong growth outlook, with Ibsrela revenue guidance of $410M-$430M for FY26 and a $1B target by 2029.
Analysts are overwhelmingly positive, with multiple firms raising price targets to a range of $13-$19 and maintaining Buy or Strong Buy ratings. Analysts highlight Ardelyx's strong execution, underpenetrated IBS-C market, and extended IP protection as key drivers of long-term growth.
